Alphapharm Pty Ltd v H Lundbeck A/S (No 2)
| Jurisdiction | Australia Federal only |
| Court | Federal Court |
| Neutral Citation | 2008-0424 FCA A,2008-0710 FCA A |
| Date | 2008 |
-
- This document is available in original version only for vLex customers
View this document and try vLex for 7 days - TRY VLEX
- This document is available in original version only for vLex customers
15 cases
-
Generics (UK) Ltd v Daiichi Pharmaceutical Company Ltd (Costs)
...patents ( Unipharm v Lundbeck, 3 rd February 2009, upheld on appeal by Judge Sobel on 25 th May 2009) and of the Australian courts ( Lundbeck v Alphapharm, 11 th June 2009 Federal Court of Appeal [2009] FCAFC 70 upholding Lindgren J [2008] FCA 57 First then, the language of the Regulation.......
- Generics (UK) Ltd v Daiichi Pharmaceutical Company Ltd (Costs)
- Apotex Pty Ltd v Sanofi-Aventis
- Citrus Queensland Pty Ltd v Sunstate Orchards Pty Ltd (No 7)
Request a trial to view additional results
3 firm's commentaries
-
Infringement Of Method Claims By Threatened Importation Clarified By The Full Federal Court
...recognised that the construction proposed by Apotex was specifically rejected by Justice Lindgren in Alphapharm Pty Ltd v H Lundbeck A/S [2008] FCA 559, where his Honour observed that if this construction was correct, where an invention is for a method or process, the reference to "imp......
-
Case Note: H Lundbeck A/S v Sandoz Pty Ltd [2019] APO 18 - patent licence
...of Therapeutic Goods (ARTG). However, it was subsequently found in a Full Federal Court decision ( Alphapharm Pty Ltd v H Lundbeck A/S [2008] FCA 559, 76 IPR 618) that the extension was incorrectly based on the inclusion of Lexapro® in the Australian Register of Therapeutic Goods (ARTG) and......
-
Differences in Trans-Tasman patent law: extension of term for pharmaceuticals
...the patentee who will generally sponsor inclusion on the ARTG; this marks the expected beginning of their exploitation (as per Alphapharm [2008] FCA 559 and 76 IPR 618). The Delegate then noted an untenable "double edged sword" argument in Pfizer (No.2) [2006] FCA 1176 and 69 IPR ......